IFPMA

NOTE: IAPO is in no way responsible for the content of the Industry Partner profiles.  These have been produced using information provided by the Industry Partners.

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) represents research-based pharmaceutical companies and associations across the globe. Research-based pharmaceutical companies make a unique contribution to global health as innovators of lifesaving and life-changing medicines and vaccines, which improved millions of lives around the world. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

Partnerships and collaborations

We are committed to place patients at the center of our activities and one way of translating this commitment into reality is by building and joining multi-stakeholder partnerships and collaborations.  

Global Health Progress

To drive new and existing collaborations to support the Sustainable Development Goals (SDGs), IFPMA has launched Global Health Progress - a new knowledge hub highlighting over 250 collaborations between the innovative biopharmaceutical industry and more than 1200 partners to support the SDGs.

Access Accelerated

The Access Accelerated initiative is a partnership of over 20 biopharmaceutical companies developing innovative and sustainable solutions to improve access to non-communicable disease (NCDs) treatment and care in low- and middle income countries. Access Accelerated also partners with the World Bank and the City Cancer Challenge (CCAN) to help address the full spectrum of access barriers to NCD medicines.

Other initiatives

IFPMA is a partner of Fight the Fakes, a multi-stakeholders campaign that aims to raise awareness about the dangers of falsified medicines. The campaign seeks to build a global movement of organizations and individuals who will shine light on the negative impact that fake medicines have on people around the globe and to reduce the negative consequences on individuals worldwide. IFPMA hosts the Secretariat of the AMR Industry Alliance, a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. To support the next generation of public health leaders in Africa, IFPMA, together with the Centre on Global Health Security at Chatham House and the Global Health Centre at the Graduate Institute, established the African Global Health Leaders Fellowship.

Since ethical business practices are at the heart of patient-centered healthcare, IFPMA holds since 2018 the industry Co-Chair of the Business Ethics for APEC SMEs Initiative, the world’s largest public-private partnership to strengthen ethical business practices in the biopharmaceutical sector (overseen by US Department of Commerce). One of the Initiative’s goals is to introduce national ethics accords between industry and non-industry health bodies, the so called Consensus Frameworks.  Both IAPO and IFPMA are signatory partners of the Global Consensus Framework for Ethical Collaboration.

Placing patients at the center

IFPMA remains committed to ensuring that patients’ interests are protected and is a strong supporter of organizations that seek to educate and represent patients, such as IAPO. Therefore, IFPMA and IAPO jointly launched an advisory Note for Guidance for IFPMA member companies and associations worldwide on best practice for interaction with patients, caregivers, and patient organizations, complementing IFPMA’s Code of Practice.

www.ifpma.org